AUA 2018 Prostate Cancer - Results from #77

Viewing 78-97 of 109 articles

AUA 2018: Debate - Treatment of High Risk Advanced and M1 Disease: Is There a Role for Treatment of the Primary? (CON)

AUA 2018: Prostate Cancer Biomarkers for Prognosis and Treatment Decision Making

AUA 2018: Risk Stratification for Active Surveillance: mp-MRI

AUA 2018: Implementation of a Novel Point of Care PCR Test to Guide Antibiotic Prophylaxis Prior to Transrectal Prostate Biopsy

AUA 2018: Engaging the Immune System to Combat Prostate Cancer

AUA 2018: Long-Term Impact of 7-year Finasteride Therapy on Prostate Cancer Incidence and Disease-Specific Mortality

AUA 2018: Donald S. Coffey Lecture

AUA 2018: Journal of Urology: Top Papers in Prostate and Testis

AUA 2018: MRI-Guided Transurethral Ultrasound Ablation in Patients with Localized Prostate Cancer: 3-Year Outcomes of a Prospective Phase I Study

AUA 2018: Population-Based Outcomes of Men with a Single Negative Prostate Biopsy: Importance of Continued Follow Up Among Older Patients

AUA 2018: Disparities in the Diagnosis and Management of Metastatic Prostate Cancer in Young Men

AUA 2018: Prostate Cancer Incidence and Mortality among Men using Statins and Non-Statin Lipid-Lowering Medications

AUA 2018: Association between Androgen-Deprivation Therapy and Non-Prostate Cancer Mortality among Men with Non-Metastatic Prostate Cancer

AUA 2018: Who Dies from Prostate Cancer? A Comprehensive Analysis of a Large Series of Patients Treated with Radical Prostatectomy with Long-Term Follow-Up

AUA 2018: Oncologic Surveillance After Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients: A Novel Risk-Based Approach

AUA 2018: Overall Survival in Patients with Primary Bone Metastatic Prostate Cancer Receiving ADT or ADT plus Concurrent Radiation Therapy: HORRAD Trial

AUA 2018: Prostate Cancer Tumor Board

AUA 2018: Health-Related Quality of Life in Patients with mCRPC Treated with Cabazitaxel, CAPRISTANA

AUA 2018: Neoadjuvant Enzalutamide and ADT in High-Risk Prostate Cancer: Initial Imaging and Surgical Findings from a Phase II Clinical Trial

AUA 2018: Clinical Experience with Lutetium 177-labeled PSMA-I&T for Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer

1
2
3
4
5
6